Long pentraxin-3 measured at late phase associated with GRACE risk scores in patients with non-ST elevation acute coronary syndrome and coronary stenting

Turk Kardiyoloji Dernegi Arsivi

Volumn 40, Issue 3, 2012, Pages 205-212

  Saygi, Serkan ^a   Kirilmaz, Bahadir ^a   Tengiz, Istemihan ^b   Türk, Uǧur Önsel ^c   Yildiz, Hicran ^a   Tüzün, Nurullah ^c   Alioǧlu, Emin ^b   Tamer, Gülden Sönmez ^d   Ercan, Ertuǧrul ^b  

^a ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

^b IZMIR UNIVERSITY   (Turkey)

^c Central Hospital Izmir   (Turkey)

^d KOCAELI UNIVERSITY   (Turkey)

Author keywords

Acute coronary syndrome; Angina pectoris; Atherosclerosis C reactive protein; GRACE risk score; Myocardial infarction; Pentraxin

Indexed keywords

PENTRAXIN 3;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY STENT; DIABETES MELLITUS; FEMALE; GLOBAL REGISTRY OF ACUTE CORONARY EVENT RISK SCORING SYSTEM; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MALE; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; SCORING SYSTEM; STABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA, STABLE; C-REACTIVE PROTEIN; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RISK ASSESSMENT; SERUM AMYLOID P-COMPONENT; STENTS;

EID: 84864198431     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: 10.5543/tkda.2012.90083     Document Type: Article

References (20)

1. Karha J, Bavry AA, Rajagopal V, Henderson MR, Ellis SG, Brener SJ. Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent. Am J Cardiol 2006;98:616-8. (Pubitemid 44233457)
2. Gach O, Legrand V, Biessaux Y, Chapelle JP, Vanbelle S, Pierard LA. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol 2007;99:31-5. (Pubitemid 44969338)
3. Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 2010;20:35-40.
4. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:e10-4.
5. Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, Castellano M, et al. Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem 1997;272:8172-8. (Pubitemid 27147769)
6. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-41. (Pubitemid 30640663)
7. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Lipid Assessment Trial Italian Network (LATIN) Investigators. Circulation 2004;110:2349-54. (Pubitemid 39407338)
8. GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141:190-9.
9. Lee DH, Jeon HK, You JH, Park MY, Lee SJ, Kim SS, et al. Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome. Korean Circ J 2010;40:370-6.
10. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:e1-121.
11. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51:606. (Pubitemid 13187192)
12. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008;215:48-55. (Pubitemid 351619875)
13. Kume N, Mitsuoka H, Hayashida K, Tanaka M. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with ~biomarkers for cardiac damage. J Cardiol 2011;58:38-45.
14. Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, et al. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 2008;197:368-74. (Pubitemid 351273259)
15. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97. (Pubitemid 38419992)
16. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
17. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9. (Pubitemid 26360452)
18. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors ~of acute myocardial infarction predictive role of C-reactive ~protein. J Am Coll Cardiol 2006;47:962-8.
19. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997;96:778-84. (Pubitemid 27329609)
20. Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, Ishikawa M, et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010;210:220-5.